Eli Lilly expanded its partnership with Insilico Medicine, converting a software licensing arrangement into a joint drug‑discovery collaboration with disclosed potential value above $100 million. The deal combines Insilico’s Pharma.AI platform with Lilly’s development and disease expertise to co‑discover therapies on Lilly‑defined targets. Both companies said financial terms include upfront payments, milestones and royalties; they did not disclose target areas beyond Lilly’s stated interest in metabolic diseases, oncology and inflammation.